Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.73 |
| ▸ | ESRRG | P62508 | 18/20 | 0.68 |
| ▸ | ESRRB | O95718 | 6/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20842111 | 1.00 | ESR1 (0.73) | ESR1ESRRGESRRBKCNH2 | |
| SCHEMBL1151938 | 1.00 | ESR1 (0.73) | ESR1ESRRGESRRBKCNH2 | |
| SCHEMBL24354499 | 0.92 | ESR1 (0.68) | ESR1ESRRGESRRBKCNH2 | |
| SCHEMBL9860588 | 0.91 | PTGS2 (0.68) | ESR1ESRRGESRRB | |
| SCHEMBL1151987 | 0.89 | ESR1 (0.71) | ESR1ESRRGESRRB | |
| SCHEMBL1151879 | 0.89 | ESR1 (0.71) | ESR1ESRRGESRRB | |
| SCHEMBL2229348 | 0.89 | ESR1 (0.71) | ESR1ESRRGESRRB | |
| SCHEMBL5725055 | 0.89 | ESR1 (0.71) | ESR1ESRRGESRRB | |
| SCHEMBL1151880 | 0.89 | ESR1 (0.71) | ESR1ESRRGESRRB | |
| SCHEMBL1151986 | 0.89 | ESR1 (0.71) | ESR1ESRRGESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0095875-B1 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos Group Ltd. (FI) | 1986-09-10 | — | — | EP | claimed |
| EP-0095875-A2 | Novel tri-phenyl alkane and alkene derivatives and their preparation and use | Farmos Group Ltd. (FI) | 1983-12-07 | — | — | EP | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
| US-4996225-A | Antitumor agents | FARMOS GROUP LTD. (FI) | 1991-02-26 | — | — | US | disclosed |
| US-4696949-A | ANTITUMOR AGENTS, ANTIESTROGENS | FARMOS GROUP LTD. (FI) | 1987-09-29 | — | — | US | disclosed |
| EP-0095875-B1 | NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos Group Ltd. (FI) | 1986-09-10 | — | — | EP | disclosed |
| EP-0095875-A2 | Novel tri-phenyl alkane and alkene derivatives and their preparation and use | Farmos Group Ltd. (FI) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ESR1 4577/4885ESRRG 1633/4885ESRRB 4733/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | ESR1 4577/4885ESRRG 1633/4885ESRRB 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.